Phase 3 Recruiting Academic/Other
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in Indiana: - IU Health West Hospital — Avon, Indiana
- IU Health North Hospital — Carmel, Indiana
- UChicago Medicine Northwest Indiana — Crown Point, Indiana
- Parkview Regional Medical Center — Fort Wayne, Indiana
- Goshen Center for Cancer Care — Goshen, Indiana
Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in Indiana: - IU Health West Hospital — Avon, Indiana
- IU Health North Hospital — Carmel, Indiana
- Northwest Cancer Center - Main Campus — Crown Point, Indiana
- UChicago Medicine Northwest Indiana — Crown Point, Indiana
- Northwest Oncology LLC — Dyer, Indiana
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of continuation of treatment with pembrolizumab (usual approach) to observation only at preventing cancer from coming back in patients with early-stage triple-negative breast cancer (TNBC) who achie…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05812807
Sites in Indiana: - IU Health West Hospital — Avon, Indiana
- IU Health North Hospital — Carmel, Indiana
- Northwest Cancer Center - Crown Point — Crown Point, Indiana
- UChicago Medicine Northwest Indiana — Crown Point, Indiana
- Northwest Oncology LLC — Dyer, Indiana
Phase 3 Recruiting Academic/Other
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radi…
Sponsor: NRG Oncology
NCT ID: NCT04852887
Sites in Indiana: - IU Health West Hospital — Avon, Indiana
- IU Health North Hospital — Carmel, Indiana
- Northwest Cancer Center - Main Campus — Crown Point, Indiana
- UChicago Medicine Northwest Indiana — Crown Point, Indiana
- Northwest Oncology LLC — Dyer, Indiana
Phase 3 Recruiting Network
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in Indiana: - Franciscan Health Indianapolis — Indianapolis, Indiana
- Franciscan Saint Elizabeth Health - Lafayette East — Lafayette, Indiana
- Franciscan Health Mooresville — Mooresville, Indiana
- Reid Health — Richmond, Indiana
- Union Hospital — Terre Haute, Indiana
Phase 3 Recruiting Academic/Other
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …
Sponsor: NRG Oncology
NCT ID: NCT06748222
Sites in Indiana: - Goshen Center for Cancer Care — Goshen, Indiana
- Baptist Health Floyd — New Albany, Indiana
- Memorial Hospital of South Bend — South Bend, Indiana
Phase 3 Recruiting NIH
This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast cancer with low risk of the cancer ret…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07391774
Sites in Indiana: - IU Health West Hospital — Avon, Indiana
- IU Health North Hospital — Carmel, Indiana
- Indiana University/Melvin and Bren Simon Cancer Center — Indianapolis, Indiana
Phase 3 Recruiting Industry
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early b…
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT06492616
Sites in Indiana: - Northwest Cancer Centers, PC — Dyer, Indiana
Phase 3 Recruiting Industry
The purpose of the study is to assess the efficacy and safety of the addition of Tersolisib (LY4064809/STX-478) to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth factor recept…
Sponsor: Eli Lilly and Company
NCT ID: NCT07174336
Sites in Indiana: - Indiana University Health University Hospital — Indianapolis, Indiana
- Hematology Oncology of Indiana — Indianapolis, Indiana
- Deaconess GI Specialty Center — Newburgh, Indiana
Phase 3 Recruiting Industry
This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metasta…
Sponsor: BriaCell Therapeutics Corporation
NCT ID: NCT06072612
Sites in Indiana: - Northwest Cancer Center — Dyer, Indiana
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in th…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06966700
Sites in Indiana: - Fort Wayne Medical Oncology and Hematology ( Site 0084) — Fort Wayne, Indiana
- Franciscan Health ( Site 0077) — Indianapolis, Indiana
Phase 3 Recruiting Industry
This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutati…
Sponsor: Relay Therapeutics, Inc.
NCT ID: NCT06982521
Sites in Indiana: - Community Health Network, Inc — Indianapolis, Indiana
Phase 3 Recruiting Industry
A study to assess the efficacy and safety of Dato-DXd in the pre-chemotherapy setting for patients with metastatic HR-positive, HER2 IHC 0 breast cancer.
Sponsor: AstraZeneca
NCT ID: NCT07205822
Sites in Indiana: - Research Site — Fort Wayne, Indiana
Phase 2 Recruiting Academic/Other
This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of …
Sponsor: Dana-Farber Cancer Institute
NCT ID: NCT04893109
Sites in Indiana: - Indiana University Health Joe & Shelly Schwarz Cancer Center — Carmel, Indiana
- IU Health North Hospital — Carmel, Indiana
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center — Indianapolis, Indiana
- Indiana University Sidney and Lois Eskenazi Hospital — Indianapolis, Indiana
Phase 2 Recruiting Academic/Other
This phase II trial tests whether low-dose aspirin can affect markers of inflammation in postpartum (after childbirth) women planning to have a breast biopsy. Chronic inflammation may increase the risk of postpartum related breast cancer. …
Sponsor: Mayo Clinic
NCT ID: NCT05557877
Sites in Indiana: - Indiana University Simon Comprehensive Cancer Center — Indianapolis, Indiana
Phase 1 Recruiting Industry
This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients w…
Sponsor: Relay Therapeutics, Inc.
NCT ID: NCT05216432
Sites in Indiana: - Community Health Network — Indianapolis, Indiana
Phase 1 Recruiting Industry
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase…
Sponsor: Eli Lilly and Company
NCT ID: NCT06465069
Sites in Indiana: - IU Simon Cancer Center — Indianapolis, Indiana
Phase 1 Recruiting Academic/Other
The goal of this study is to test an investigational vaccine to activate the immune system to fight breast cancer.
Sponsor: Pravin T.P Kaumaya
NCT ID: NCT06949410
Sites in Indiana: - Indiana University Melvin & Bren Simon Comprehensive Cancer Center — Indianapolis, Indiana
NA Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of ctDNA-guided initiation of CDK4/6 inhibitor therapy using the Signatera™ Designed on Genome test (referred to as "Signatera Genome") in participants with intermediate-risk…
Sponsor: Natera, Inc.
NCT ID: NCT07214532
Sites in Indiana: - Northwest Cancer Center — Dyer, Indiana
- Indiana University — Indianapolis, Indiana
Recruiting Academic/Other
This study will assess whether a quantitative, HER2 assay can accurately and reliably discriminate between responders and non-responders among patients with HER2 IHCI+ metastatic breast cancer who are receiving T-Dxd.
Sponsor: Abramson Cancer Center at Penn Medicine
NCT ID: NCT06551116
Sites in Indiana: - University of Chicago Medicine Northwest Indiana — Crown Point, Indiana
Recruiting Industry
The BEGIN Study by BostonGene and Exigent Genomic INsight evaluates the efficacy of comprehensive molecular testing in advanced cancer patients. Using the BostonGene Tumor Portrait test, the study aims to identify actionable findings, asse…
Sponsor: BostonGene
NCT ID: NCT06272864
Sites in Indiana: - Fort Wayne Medical Oncology and Hematology — Fort Wayne, Indiana
NA Recruiting Academic/Other
The purpose of this study is to study exercise in a novel population with indolent MBC (no progression on current therapy in prior 12 months and not receiving cytotoxic chemotherapy). The study team hypothesizes that delivering virtual, su…
Sponsor: Indiana University
NCT ID: NCT05468034
Sites in Indiana: - IU Health West — Avon, Indiana
- IU Health Joe and Shelly Schwarz Cancer Center — Carmel, Indiana
- Indiana University Melvin & Bren Simon Cancer Center — Indianapolis, Indiana
- Sidney and Lois Eskenazi Hospital — Indianapolis, Indiana